Anti-drug antibodies in the current management of cancer-Reference-Cited by-同舟云学术

Anti-drug antibodies in the current management of cancer

Published:2022-03-25 Issue:5 Volume:89 Page:577-584
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Borregón Miguel,Martínez Katherine,Ramos Alba,Ramos Irene,Berzal Beatriz,Mazariegos Manuel,Martínez Elia,Hernández Tatiana,Doger Bernard,Moreno Víctor^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04418-2.pdf

Reference55 articles.

1. Chan JCN, Chan ATC (2017) Biologics and biosimilars: what, why and how? ESMO Open. 2(1):e000180. https://doi.org/10.1136/esmoopen-2017-000180 (Published 2017 Mar 24)

2. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9(4):325–338. https://doi.org/10.1038/nrd3003

3. van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH (2016) Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist 21(10):1260–1268. https://doi.org/10.1634/theoncologist.2016-0061

4. Baldo BA (2013) Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2(10):e26333. https://doi.org/10.4161/onci.26333

5. Vaisman-Mentesh A, Rosenstein S, Yavzori M et al (2019) Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists. Front Immunol 10:2921. https://doi.org/10.3389/fimmu.2019.02921 (Published 2019 Dec 18)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer;International Immunopharmacology;2024-08

3. Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial;Gynecologic Oncology;2024-08

4. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?;American Journal of Clinical Dermatology;2024-07-13

5. MicroRNA-5196 as an Accurate Biomarker of Disease Activity and Response to Treatment in Rheumatoid Arthritis;Journal of Contemporary Medical Sciences;2024-04-30